Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
New Studies Reveal Potential Mechanisms of Resistance to CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
Home
Publications
New Studies Reveal Potential Mechanisms of Resistance to CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
New Studies Reveal Potential Mechanisms of Resistance to CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Download PDF
Download
Open Access
Publisher website
Google Scholar
28 June 2021
journal article
editorial
Published by
Oxford University Press (OUP)
in
The Oncologist
Vol. 26
(S3)
,
S13-S14
DOI:
10.1002/onco.13875
PMID:
34181796
PMCID:
PMC8262301
Abstract
Research focused on barriers to the real-world use of CDK4/6 inhibitor therapy in patients with HR+/HER2– breast cancer reveals potential mechanisms and biomarkers of drug resistance.
Keywords
BREAST CANCER
POTENTIAL MECHANISMS
STUDIES REVEAL
CANCER RESEARCH
REVEAL POTENTIAL
CANCER REVEALS
RESEARCH FOCUSED
INHIBITOR THERAPY
DRUG RESISTANCE
BREAST
Related articles
Cited
Cited by 1 article
Scroll to top